Trial · NCT02360397
Ranolazine Mediated PVC Reduction in Ischemic Heart Disease
NCT02360397, Phase 2, Completed, Kent Hospital, Rhode Island; results first posted 2020-01-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ranolazine Mediated PVC Reduction in Ischemic Heart Disease. Trials, record NCT02360397. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02360397
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ranolazine Mediated PVC Reduction in Ischemic Heart Disease
- NCT number
- NCT02360397
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 6 participants, actual
- Lead sponsor
- Kent Hospital, Rhode Island
- Conditions
- Ventricular Premature Complexes, Myocardial Ischemia
- Interventions
- ranolazine
- First posted
- 2015-02-10
- Last updated
- 2020-01-29
- Results first posted
- 2020-01-29
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Effect of Ranolazine on the PVC Burden Over 30 Days | Baseline (7 day) Holter compared to day 30 (7 day) Holter | The change in percentage of PVC burden after taking Ranolazine 1000mg twice daily for 30 days |
| Primary | The Effect of Ranolazine on Cardiac Ischemia | Baseline and day 30 | The effect of ranolazine on cardiac ischemia as measured by change in millimeters of ST segment deviation on ECG monitoring at Baseline and after 30 days of Ranolazine therapy (day 30). |
| Secondary | Score on Seattle Angina Questionnaire at Baseline and at Day 30 | Baseline and day 30 | The SAQ quantifies patients' physical limitations caused by angina, the frequency of and recent changes in their symptoms, their satisfaction with treatment, and the degree to which they perceive their disease to affect their quality of life. Each scale is transformed to a score of 0 to 100, where higher scores indicate better function (eg, less physical limitation, less angina, and better quality of life). Angina symptoms may be felt as: chest pain, a heaviness, tightness or squeezing sensation in the chest, aching across the chest, particularly behind the breastbone. The pain may radiate to the neck, jaw, arms, back or teeth. |
| Secondary | Number of Non-sustained Ventricular Tachycardia and Sustained Ventricular Arrhythmia Episodes on Holter Monitoring | Baseline and Day 30 | Number of non-sustained ventricular tachycardia episodes (\>8 beats) and sustained ventricular arrhythmia episodes on Holter monitoring at baseline and at 30 days |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Effect of Ranolazine on the PVC Burden Over 30 Days | Baseline (7 day) Holter compared to day 30 (7 day) Holter | The percentage of PVC's on Holter monitor at baseline compared to day 30 were used to determine the statistical significance of the data. | percentage of PVC burden | MEAN |
| PRIMARY | The Effect of Ranolazine on Cardiac Ischemia | Baseline and day 30 | millimeters | MEAN | |
| SECONDARY | Score on Seattle Angina Questionnaire at Baseline and at Day 30 | Baseline and day 30 | Score on Seattle Angina Questionnaire at Baseline and at day 30. | score on a scale | MEAN |
| SECONDARY | Number of Non-sustained Ventricular Tachycardia and Sustained Ventricular Arrhythmia Episodes on Holter Monitoring | Baseline and Day 30 | number of episodes | NUMBER |
Source ClinicalTrials.gov
Results by group13
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Effect of Ranolazine on the PVC Burden Over 30 Days | Ranolazine | percentage of PVC burden at Baseline | 5.71 | Full Range 5.52 to 9.73 | percentage of PVC burden |
| The Effect of Ranolazine on the PVC Burden Over 30 Days | Ranolazine | percentage of PVC burden at Day 30 | 5.495 | Full Range 1.2 to 9.73 | percentage of PVC burden |
| The Effect of Ranolazine on Cardiac Ischemia | Effect of Ranolazine on Cardiac Ischemia | 0 | Full Range 0 to 0 | millimeters | |
| Score on Seattle Angina Questionnaire at Baseline and at Day 30 | Ranolazine | Baseline SAQ score for Angina Frequency | 95 | Full Range 90 to 100 | score on a scale |
| Score on Seattle Angina Questionnaire at Baseline and at Day 30 | Ranolazine | Day 30 SAQ score for Angina Frequency | 95 | Full Range 90 to 100 | score on a scale |
| Score on Seattle Angina Questionnaire at Baseline and at Day 30 | Ranolazine | Baseline score for Angina Stability | 50 | Full Range 50 to 50 | score on a scale |
| Score on Seattle Angina Questionnaire at Baseline and at Day 30 | Ranolazine | Day 30 SAQ score for Angina Stability | 50 | Full Range 50 to 50 | score on a scale |
| Score on Seattle Angina Questionnaire at Baseline and at Day 30 | Ranolazine | Baseline SAQ score for Physical Limitation | 94.445 | Full Range 88.89 to 100 | score on a scale |
| Score on Seattle Angina Questionnaire at Baseline and at Day 30 | Ranolazine | Day 30 SAQ score for Physical Limitation | 94.445 | Full Range 88.89 to 100 | score on a scale |
| Score on Seattle Angina Questionnaire at Baseline and at Day 30 | Ranolazine | Baseline SAQ score for Day 30 SAQ score Quality of | 79.165 | Full Range 58.33 to 100 | score on a scale |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ranolazine | 6 | |
| Overall Study | COMPLETED | Ranolazine | 2 | |
| Overall Study | NOT COMPLETED | Ranolazine | 4 |
Source ClinicalTrials.gov
Adverse events1
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Syncopy | Cardiac disorders | Ranolazine | 1 | 6 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Ranolazine | 0 | 6 |
| Total, other adverse events | Ranolazine | 0 | 6 |
| Total, serious adverse events | Ranolazine | 1 | 6 |
Source ClinicalTrials.gov
Papers14
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02360397
GET https://conductscience.org/api/trials/v1/NCT02360397/registered